Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/13/2026, 9:34:27 PM
Content snapshot
{ "session_id": "sess_SDA-2026-04-13-gap-pubmed-20260410-143119-8ae42941", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "minimax:MiniMax-M2.7", "action": "synthesize", "content": "\n\n```json\n{\n \"ranked_hypotheses\": [\n {\n \"rank\": 1,\n \"id\": \"H6\",\n \"title\": \"HSP90B1 ERES Formation for Aggregate Secretion\",\n \"theorist_confidence\": 0.44,\n \"skeptic_confidence\": 0.24,\n \"expert_confidence\": 0.24,\n \"composite_score\": 0.36,\n \"scores\": {\n \"mechanistic_plausibility\": 0.35,\n \"evidence_strength\": 0.35,\n \"novelty\": 0.40,\n \"feasibility\": 0.25,\n \"therapeutic_potential\": 0.40,\n \"druggability\": 0.40,\n \"safety_profile\": 0.25,\n \"competitive_landscape\": 0.35,\n \"data_availability\": 0.30,\n \"reproducibility\": 0.30\n },\n \"evidence_for\": [\n {\"claim\": \"HSP90B1/GRP94 is an ER chaperone essential for unconventional secretion under proteostatic stress\", \"pmid\": \"29987195\"},\n {\"claim\": \"TFG regulates ERES organization and unconventional protein trafficking\", \"pmid\": \"23091053\"},\n {\"claim\": \"ER stress is activated in ALS motor neurons\", \"pmid\": \"28704975\"},\n {\"claim\": \"HSP90B1 is a tractable drug target with existing inhibitors (NVP-HSP990, PU-H71)\", \"pmid\": \"26124442\"},\n {\"claim\": \"PIKFYVE inhibition activates compensatory ER stress responses\", \"pmid\": \"36754049\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"ERES formation is definitionally COPII-dependent; 'COPII-independent ERES' has no biochemical mechanism\", \"pmid\": \"23091053\"},\n {\"claim\": \"HSP90B1 is an ER lumen chaperone with no demonstrated membrane-nucleating function\", \"pmid\": \"29987195\"},\n {\"claim\": \"TFG mutations cause neuropathy by impairing ER export (HSP), supporting TFG as export-promoting, not enhancing secretion\", \"pmid\": \"23091053\"},\n {\"claim\": \"ER stress typically activates ERAD, not unconventional secretion\", \"pmid\": \"28704975\"},\n {\"claim\": \"HSP90 inhibitors have narrow therapeutic windows and cause liver toxicity\", \"pmid\": \"26124442\"}\n ],\n \"key_gaps\": [\n \"No mechanism exists for COPII-independent ERES formation\",\n \"HSP90B1 lumenal location incompatible with membrane organization\",\n \"TFG biology contradicts enhanced ERES model\"\n ],\n \"required_experiments\": [\n \"SEC16A and LC3B colocalization during PIKFYVE inhibition\",\n \"HSP90B1 knockout blocks therapeutic benefit (falsification test)\",\n \"COPII-independent ER export reconstitution assay\"\n ],\n \"red_flags\": [\"COPII-independent mechanism lacks biochemical validation\"]\n },\n {\n \"rank\": 2,\n \"id\": \"H2\",\n \"title\": \"RAB27A/ALIX Lysosomal Exocytosis\",\n \"theorist_confidence\": 0.48,\n \"skeptic_confidence\": 0.28,\n \"expert_confidence\": 0.28,\n \"composite_score\": 0.31,\n \"scores\": {\n \"mechanistic_plausibility\": 0.25,\n \"evidence_strength\": 0.30,\n \"novelty\": 0.45,\n \"feasibility\": 0.20,\n \"therapeutic_potential\": 0.35,\n \"druggability\": 0.35,\n \"safety_profile\": 0.15,\n \"competitive_landscape\": 0.25,\n \"data_availability\": 0.25,\n \"reproducibility\": 0.25\n },\n \"evidence_for\": [\n {\"claim\": \"ALIX interactions with ubiquitinated cargo are well-characterized in endosomal sorting\", \"pmid\": \"16903783\"},\n {\"claim\": \"RAB27A specifically controls lysosomal exocytosis in specialized secretory cells\", \"pmid\": \"15102840\"},\n {\"claim\": \"Protein aggregates in ALS are ubiquitinated and accumulate on late endosomes\", \"pmid\": \"32873930\"},\n {\"claim\": \"ALIX is a druggable target via Bro1 domain protein-protein interaction modulators\", \"pmid\": \"16903783\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"PIKFYVE inhibition blocks autophagosome-lysosome fusion, making simultaneous lysosome exocytosis paradoxical\", \"pmid\": \"22990836\"},\n {\"claim\": \"ALIX is recruited via ESCRT-III interactions, not PI(3,5)P2\", \"pmid\": \"16903783\"},\n {\"claim\": \"ALIX knockdown causes tauopathy phenotypes, exacerbating aggregate accumulation\", \"pmid\": \"29189420\"},\n {\"claim\": \"RAB27A is cell-type restricted (melanosomes, lytic granules) and dispensable for lysosomal exocytosis in most cells\", \"pmid\": \"22573891\"},\n {\"claim\": \"Late endosomal ubiquitinated aggregates represent defective sorting, not functional clearance\", \"pmid\": \"32873930\"}\n ],\n \"key_gaps\": [\n \"Mechanistic paradox: fusion-defective lysosomes cannot simultaneously exocytose\",\n \"No PI(3,5)P2-RAB27A regulatory link exists\",\n \"RAB27A cell-type restriction excludes motor neurons\"\n ],\n \"required_experiments\": [\n \"TIRF microscopy for real-time lysosome-plasma membrane fusion events\",\n \"RAB27A CRISPR knockout in motor neurons\",\n \"Subcellular fractionation to determine aggregate localization\"\n ],\n \"alternative_interpretation\": \"Aggregates may load onto exosomes (MVBs fuse with PM) rather than direct lysosome exocytosis—late endosomes/MVBs may retain fusion competency while autophagosomes do not\",\n \"red_flags\": [\"Fundamental mechanistic paradox unresolved\", \"ALIX loss-of-function causes neurodegeneration\"]\n },\n {\n \"rank\": 3,\n \"id\": \"H4\",\n \"title\": \"YKT6 SNARE Fusion for Aggregate Exocytosis\",\n \"theorist_confidence\": 0.45,\n \"skeptic_confidence\": 0.25,\n \"expert_confidence\": 0.25,\n \"composite_score\": 0.29,\n \"scores\": {\n \"mechanistic_plausibility\": 0.30,\n \"evidence_strength\": 0.30,\n \"novelty\": 0.50,\n \"feasibility\": 0.20,\n \"therapeutic_potential\": 0.35,\n \"druggability\": 0.30,\n \"safety_profile\": 0.25,\n \"competitive_landscape\": 0.20,\n \"data_availability\": 0.25,\n \"reproducibility\": 0.25\n },\n \"evidence_for\": [\n {\"claim\": \"YKT6 is essential for unconventional protein secretion of leaderless proteins\", \"pmid\": \"29107332\"},\n {\"claim\": \"SNAP23/STX4 are plasma membrane SNAREs functioning in regulated exocytosis\", \"pmid\": \"11839689\"},\n {\"claim\": \"PIKFYVE inhibition alters membrane lipid composition affecting SNARE dynamics\", \"pmid\": \"29273643\"},\n {\"claim\": \"Secretory autophagy (autophagosome-PM fusion) bypasses classical secretion\", \"pmid\": \"25468908\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"YKT6 canonically forms SNARE complexes with SNAP29 and STX17, not STX4\", \"pmid\": \"29107332\"},\n {\"claim\": \"Proposed YKT6-SNAP23-STX4 complex is not a known biological combination\", \"pmid\": \"29107332\"},\n {\"claim\": \"YKT6-mediated unconventional secretion handles soluble monomers, not aggregates\", \"pmid\": \"29107332\"},\n {\"claim\": \"PIKFYVE inhibition causes vacuolation impairing general secretion\", \"pmid\": \"22990836\"},\n {\"claim\": \"Plasma membrane-lysosome hybrid organelles are not well-characterized\", \"pmid\": \"29107332\"}\n ],\n \"key_gaps\": [\n \"Non-standard SNARE complex lacks biochemical validation\",\n \"PI(3,5)P2 depletion-YKT6 relocalization entirely speculative\",\n \"Organelle identity problem for hybrid compartments\"\n ],\n \"required_experiments\": [\n \"YKT6 CRISPR knockout blocks aggregate clearance (falsification)\",\n \"Mass spectrometry of conditioned media for SNARE complexes\",\n \"Biochemical rescue with YKT6 variants (palmitoylation mutant, PM-targeted)\"\n ],\n \"red_flags\": [\"Non-standard SNARE complex proposed\", \"Aggregates cannot be packaged into conventional vesicles\"]\n },\n {\n \"rank\": 4,\n \"id\": \"H1\",\n \"title\": \"TMED10 CUPS Pathway for Aggregate Secretion\",\n \"theorist_confidence\": 0.52,\n \"skeptic_confidence\": 0.31,\n \"expert_confidence\": 0.31,\n \"composite_score\": 0.28,\n \"scores\": {\n \"mechanistic_plausibility\": 0.20,\n \"evidence_strength\": 0.25,\n \"novelty\": 0.40,\n \"feasibility\": 0.15,\n \"therapeutic_potential\": 0.40,\n \"druggability\": 0.15,\n \"safety_profile\": 0.20,\n \"competitive_landscape\": 0.20,\n \"data_availability\": 0.25,\n \"reproducibility\": 0.20\n },\n \"evidence_for\": [\n {\"claim\": \"TMED10 channel identified as central component of CUPS pathway under proteostatic stress\", \"pmid\": \"31722219\"},\n {\"claim\": \"TDP-43 and FUS are known substrates of unconventional secretion mechanisms\", \"pmid\": \"29395064\"},\n {\"claim\": \"ALS-linked proteins enter unconventional secretion under stress\", \"pmid\": \"29395064\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"TMED10 channel (~1nm pore) cannot translocate aggregated insoluble proteins\", \"pmid\": \"31722219\"},\n {\"claim\": \"PI(3,5)P2-TMED10 link is entirely inferred with no demonstrated lipid-protein interaction\", \"pmid\": \"31722219\"},\n {\"claim\": \"CUPS pathway characterized in HeLa cells, not validated in motor neurons\", \"pmid\": \"31722219\"},\n {\"claim\": \"TMED10 mutations cause congenital disorders of glycosylation, impairing secretion\", \"pmid\": \"29395064\"},\n {\"claim\": \"UPR activated by PIKFYVE inhibition would reduce TMED10 flux, not increase it\", \"pmid\": \"28704975\"}\n ],\n \"key_gaps\": [\n \"Fundamental substrate mismatch: CUPS handles soluble proteins, not aggregates\",\n \"No PI(3,5)P2 regulatory domain identified in TMED10\",\n \"Motor neuron validation absent\"\n ],\n \"required_experiments\": [\n \"In vitro TMED10 reconstitution with aggregated TDP-43/FUS\",\n \"TMED10 knockout blocks therapeutic benefit\",\n \"pHluorin-tagged aggregate secretion assay\"\n ],\n \"red_flags\": [\"Substrate mismatch is fatal to hypothesis\", \"CUPS is for soluble leaderless proteins\"]\n },\n {\n \"rank\": 5,\n \"id\": \"H7\",\n \"title\": \"Annexin A2/S100A10 Extracellular Degradation\",\n \"theorist_confidence\": 0.40,\n \"skeptic_confidence\": 0.21,\n \"expert_confidence\": 0.21,\n \"composite_score\": 0.26,\n \"scores\": {\n \"mechanistic_plausibility\": 0.20,\n \"evidence_strength\": 0.30,\n \"novelty\": 0.30,\n \"feasibility\": 0.20,\n \"therapeutic_potential\": 0.35,\n \"druggability\": 0.35,\n \"safety_profile\": 0.30,\n \"competitive_landscape\": 0.25,\n \"data_availability\": 0.25,\n \"reproducibility\": 0.25\n },\n \"evidence_for\": [\n {\"claim\": \"Annexin A2/S100A10 complex mediates extracellular matrix remodeling and protein clearance\", \"pmid\": \"24043799\"},\n {\"claim\": \"Annexin A2 is expressed in motor neurons and regulates membrane-cytoskeleton dynamics\", \"pmid\": \"11891219\"},\n {\"claim\": \"Extracellular proteases including plasmin degrade aggregated proteins\", \"pmid\": \"16737959\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"This is NOT an exocytosis mechanism—represents downstream extracellular proteolysis\", \"pmid\": \"24043799\"},\n {\"claim\": \"Annexin A2 lacks signal peptide and requires prior secretion via unconventional pathway\", \"pmid\": \"24043799\"},\n {\"claim\": \"Annexin A2 knockout mice are viable with minimal proteostasis phenotypes\", \"pmid\": \"24043799\"},\n {\"claim\": \"Extracellular proteolysis requires prior aggregate release—does not explain exocytosis\"}\n ],\n \"key_gaps\": [\n \"Mechanism is not exocytosis—incorrectly categorized in GAP\",\n \"Requires prior exocytosis mechanism to be primary\",\n \"Annexin A2 itself must be secreted\"\n ],\n \"required_experiments\": [\n \"ANXA2 knockout blocks extracellular aggregate degradation\",\n \"Annexin A2 secretion status during PIKFYVE inhibition\",\n \"Extracellular aggregate decoration with Annexin A2\"\n ],\n \"red_flags\": [\"Not an exocytosis hypothesis—misclassified in GAP\", \"Downstream mechanism only\"]\n },\n {\n \"rank\": 6,\n \"id\": \"H5\",\n \"title\": \"Microglial STX11 Granule Exocytosis\",\n \"theorist_confidence\": 0.38,\n \"skeptic_confidence\": 0.22,\n \"expert_confidence\": 0.22,\n \"composite_score\": 0.23,\n \"scores\": {\n \"mechanistic_plausibility\": 0.15,\n \"evidence_strength\": 0.20,\n \"novelty\": 0.35,\n \"feasibility\": 0.10,\n \"therapeutic_potential\": 0.15,\n \"druggability\": 0.30,\n \"safety_profile\": 0.15,\n \"competitive_landscape\": 0.30,\n \"data_availability\": 0.20,\n \"reproducibility\": 0.20\n },\n \"evidence_for\": [\n {\"claim\": \"STX11 controls granule exocytosis in cytotoxic lymphocytes\", \"pmid\": \"16177804\"},\n {\"claim\": \"Microglia actively phagocytose and clear debris in ALS models\", \"pmid\": \"32873930\"},\n {\"claim\": \"Motor neuron debris containing TDP-43 aggregates is cleared by non-cell-autonomous mechanisms\", \"pmid\": \"28753427\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Granule exocytosis releases granzymes for cell killing—they function intracellularly, not extracellularly\", \"pmid\": \"16177804\"},\n {\"claim\": \"STX11 mutations cause hemophagocytic lymphohistiocytosis, not aggregate clearance\", \"pmid\": \"16177804\"},\n {\"claim\": \"STX11 in microglia is associated with phagosome maturation, not granule exocytosis\", \"pmid\": \"24501467\"},\n {\"claim\": \"Purinergic receptor-mediated phagocytosis (P2RX7, P2Y12) is the established microglial debris clearance mechanism\", \"pmid\": \"28753427\"},\n {\"claim\": \"TREM2 variants are major ALS/FTD risk factors—microglial phagocytosis is TREM2-dependent\", \"pmid\": \"27974619\"}\n ],\n \"key_gaps\": [\n \"Fundamental mechanistic error: granule exocytosis cannot degrade extracellular aggregates\",\n \"STX11 localization in microglia is endosomal/phagolysosomal, not granule\",\n \"More validated microglial mechanisms exist (TREM2, P2RX7)\"\n ],\n \"required_experiments\": [\n \"Microglia-specific PIKFYVE deletion is sufficient for benefit\",\n \"Test P2RX7 and TREM2 pathways instead of STX11\",\n \"Adoptive transfer of PIKFYVE-inhibited microglia\"\n ],\n \"red_flags\": [\"Mechanism cannot perform proposed function\", \"Wrong microglial pathway\"]\n },\n {\n \"rank\": 7,\n \"id\": \"H3\",\n \"title\": \"CHCHD10/Mitochondrial-Derived Vesicle Exocytosis\",\n \"theorist_confidence\": 0.42,\n \"skeptic_confidence\": 0.19,\n \"expert_confidence\": 0.19,\n \"composite_score\": 0.20,\n \"scores\": {\n \"mechanistic_plausibility\": 0.15,\n \"evidence_strength\": 0.20,\n \"novelty\": 0.40,\n \"feasibility\": 0.10,\n \"therapeutic_potential\": 0.15,\n \"druggability\": 0.05,\n \"safety_profile\": 0.15,\n \"competitive_landscape\": 0.10,\n \"data_availability\": 0.20,\n \"reproducibility\": 0.15\n },\n \"evidence_for\": [\n {\"claim\": \"CHCHD10 mutations cause ALS and mitochondrial dysfunction\", \"pmid\": \"25261932\"},\n {\"claim\": \"Mitochondrial-derived vesicles are an emerging pathway for mitochondrial quality control\", \"pmid\": \"23870199\"},\n {\"claim\": \"PIKFYVE inhibition preserves mitochondrial function\", \"pmid\": \"36754049\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"CHCHD10 loss-of-function causes ALS—releasing CHCHD10 from mitochondria would worsen ALS\", \"pmid\": \"25261932\"},\n {\"claim\": \"MDVs fuse with lysosomes for degradation, not with autophagosomes for secretion—no exocytic MDV pathway exists\", \"pmid\": \"23870199\"},\n {\"claim\": \"Preserved mitochondria in PIKFYVE-inhibited cells likely cannot be degraded (blocked mitophagy), not protected\", \"pmid\": \"15548221\"},\n {\"claim\": \"PIKFYVE inhibition impairs lysosomal function, paradoxically blocking MDV quality control\", \"pmid\": \"22990836\"},\n {\"claim\": \"No PI(3,5)P2-regulated kinase demonstrated to phosphorylate CHCHD10\", \"pmid\": \"26083769\"}\n ],\n \"key_gaps\": [\n \"Therapeutic logic is inverted: depleting neuroprotective mitochondrial protein proposed as therapy\",\n \"No exocytic MDV pathway exists in literature\",\n \"'Protected mitochondria' interpretation likely conflates blocked mitophagy with protection\"\n ],\n \"required_experiments\": [\n \"CHCHD10 subcellular localization during PIKFYVE inhibition\",\n \"Phospho-mimetic vs phospho-dead CHCHD10 knock-in\",\n \"MDV inhibitor (glyburide) blocks therapeutic benefit\"\n ],\n \"red_flags\": [\"Inverted therapeutic logic\", \"Non-existent exocytic MDV pathway\", \"Misinterpretation of preserved mitochondria\"]\n }\n ],\n \"knowledge_edges\": [\n {\"subject\": \"PIKFYVE\", \"predicate\": \"generates\", \"object\": \"PI(3,5)P2\", \"context\": \"lipid kinase reaction\", \"pmid\": \"15548221\"},\n {\"subject\": \"PIKFYVE\", \"predicate\": \"inhibits\", \"object\": \"autophagosome-lysosome fusion\", \"context\": \"therapeutic mechanism paradox\", \"pmid\": \"22990836\"},\n {\"subject\": \"PIKFYVE\", \"predicate\": \"targeted_by\", \"object\": \"Apilimod\", \"context\": \"clinical development\", \"pmid\": \"26839307\"},\n {\"subject\": \"PIKFYVE\", \"predicate\": \"targeted_by\", \"object\": \"YM-201636\", \"context\": \"research tool\", \"pmid\": \"22990836\"},\n {\"subject\": \"PIKFYVE\", \"predicate\": \"associated_with\", \"object\": \"ALS motor neuron protection\", \"context\": \"therapeutic potential\", \"pmid\": \"36754049\"},\n {\"subject\": \"TMED10\", \"predicate\": \"part_of\", \"object\": \"CUPS pathway\", \"context\": \"unconventional secretion\", \"pmid\": \"31722219\"},\n {\"subject\": \"TMED10\", \"predicate\": \"mutated_in\", \"object\": \"Congenital disorders of glycosylation\", \"context\": \"disease relevance\", \"pmid\": \"29395064\"},\n {\"subject\": \"TDP-43\", \"predicate\": \"substrate_of\", \"object\": \"unconventional secretion\", \"context\": \"ALS pathology\", \"pmid\": \"29395064\"},\n {\"subject\": \"FUS\", \"predicate\": \"substrate_of\", \"object\": \"unconventional secretion\", \"context\": \"ALS pathology\", \"pmid\": \"29395064\"},\n {\"subject\": \"RAB27A\", \"predicate\": \"controls\", \"object\": \"lysosomal exocytosis\", \"context\": \"specialized secretory cells\", \"pmid\": \"15102840\"},\n {\"subject\": \"RAB27A\", \"predicate\": \"dispensable_for\", \"object\": \"lysosomal exocytosis in most cells\", \"context\": \"cell-type restriction\", \"pmid\": \"22573891\"},\n {\"subject\": \"ALIX\", \"predicate\": \"interacts_with\", \"object\": \"ESCRT-III/CHMP4B\", \"context\": \"endosomal sorting\", \"pmid\": \"16903783\"},\n {\"subject\": \"ALIX\", \"predicate\": \"knockdown_associated_with\", \"object\": \"tauopathy\", \"context\": \"neurodegeneration phenotype\", \"pmid\": \"29189420\"},\n {\"subject\": \"CHCHD10\", \"predicate\": \"mutated_in\", \"object\": \"ALS\", \"context\": \"mitochondrial dysfunction\", \"pmid\": \"25261932\"},\n {\"subject\": \"CHCHD10\", \"predicate\": \"regulates\", \"object\": \"mitochondrial cristae structure\", \"context\": \"via OPA1-like function\", \"pmid\": \"25261932\"},\n {\"subject\": \"CHCHD10\", \"predicate\": \"phosphorylated_by\", \"object\": \"CK2\", \"context\": \"not PI(3,5)P2-regulated\", \"pmid\": \"26083769\"},\n {\"subject\": \"MDV\", \"predicate\": \"fuses_with\", \"object\": \"lysosomes\", \"context\": \"mitochondrial quality control\", \"pmid\": \"23870199\"},\n {\"subject\": \"YKT6\", \"predicate\": \"forms_complex_with\", \"object\": \"SNAP29-STX17\", \"context\": \"canonical ER-Golgi trafficking\", \"pmid\": \"29107332\"},\n {\"subject\": \"YKT6\", \"predicate\": \"mediates\", \"object\": \"unconventional secretion\", \"context\": \"leaderless proteins\", \"pmid\": \"29107332\"},\n {\"subject\": \"STX11\", \"predicate\": \"mutated_in\", \"object\": \"Hemophagocytic lymphohistiocytosis\", \"context\": \"immune disorder\", \"pmid\": \"16177804\"},\n {\"subject\": \"STX11\", \"predicate\": \"associated_with\", \"object\": \"phagosome maturation\", \"context\": \"microglial function\", \"pmid\": \"24501467\"},\n {\"subject\": \"TREM2\", \"predicate\": \"variant_risk_factor_for\", \"object\": \"ALS/FTD\", \"context\": \"microglial phagocytosis\", \"pmid\": \"27974619\"},\n {\"subject\": \"P2RX7\", \"predicate\": \"mediates\", \"object\": \"microglial phagocytosis\", \"context\": \"debris clearance\", \"pmid\": \"28753427\"},\n {\"subject\": \"HSP90B1\", \"predicate\": \"chaperone_for\", \"object\": \"ER protein folding\", \"context\": \"ER stress response\", \"pmid\": \"29987195\"},\n {\"subject\": \"TFG\", \"predicate\": \"mutated_in\", \"object\": \"Hereditary spastic paraplegia 57\", \"context\": \"impaired ER export\", \"pmid\": \"23091053\"},\n {\"subject\": \"ANXA2\", \"predicate\": \"forms_complex_with\", \"object\": \"S100A10\", \"context\": \"membrane-cytoskeleton dynamics\", \"pmid\": \"24043799\"},\n {\"subject\": \"ER stress\", \"predicate\": \"activates\", \"object\": \"ERAD pathway\", \"context\": \"protein quality control\", \"pmid\": \"28704975\"},\n {\"subject\": \"ER-phagy receptors\", \"predicate\": \"include\", \"object\": \"FAM134B, RTN3, CCPG1\", \"context\": \"ER quality control\", \"pmid\": \"30104642\"},\n {\"subject\": \"Secretory autophagy\", \"predicate\": \"mediates\", \"object\": \"autophagosome-plasma membrane fusion\", \"context\": \"unconventional secretion\", \"pmid\": \"25468908\"},\n {\"subject", "tokens_used": "5158", "persona_id": "persona-synthesizer" }